Gritstone Bio Price to Free Cash Flow Ratio 2017-2024 | GRTSQ
Historical price to free cash flow ratio values for Gritstone Bio (GRTSQ) since 2017.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Gritstone Bio Price to Free Cash Flow Ratio Historical Data |
| Date |
Stock Price |
TTM FCF per Share |
Price to FCF Ratio |
|
0.00 |
|
nan |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
